


LIVERFAST™

Serum based diagnostic tool combining 10 biomarkers and AI technology to accurately stage Liver fibrosis, inflammatory activity, and steatosis

Features

Noninvasive test (NIT) for complete Liver assessment



Stages Liver injury for common chronic Liver diseases

- NAFLD/NASH
- CHB
- CHC
- ALD

10 Biomarkers including Liver specific proteins, plus age, gender, and BMI

- Alpha-2-Macroglobulin
- Haptoglobin
- Apolipoprotein A1
- Total Bilirubin
- GGT
- ALT
- AST
- Fasting Glucose
- Tryglyceride
- Total Cholesterol
- Age
- Gender
- BMI

Patented algorithm using AI and machine learning technology

Stratifies the severity of Liver disease from normal to cirrhosis

Benefits

- ✓ Affordable, noninvasive test for screening, diagnosis, and follow-up
- ✓ Easily repeatable for monitoring
- ✓ Easily integrates into Clinical workflows
- ✓ Simple to understand results: quantitative scores, adapted cutoffs, and color chart interpretation
- ✓ Proprietary CPT code
- ✓ CLIA Certified (US), CE Conformity Approved (EU)
- ✓ SAF scoring system staging disease without bias for each category of lesions

Contact Us
service@fibronostics.com
1-888-552-1603
www.fibronostics.com

LIVERFAST Proprietary CPT
Code 0166U

(CHB) Chronic hepatitis B, (CHC) Chronic hepatitis C, (NAFLD) Non Alcoholic Fatty Liver Disease, (NASH) Non Alcoholic Steatohepatitis, (ALD) Alcoholic Liver Disease, (GGT) Gamma Glutamyl transpeptidase, (ALT) Alanine Aminotransferase, (AST) Aspartate Aminotransferase, (BMI) Body mass index (SAF) Steatosis-Activity-Fibrosis histological scoring system, Bedossa P. et al., Hepatology 2014

